A PHASE II PROSPECTIVE STUDY OF KETOCONAZOLE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS

被引：0
|
作者：
Guadalupi, V. [1 ]
Giganti, M. O. [1 ]
Testa, I. [1 ]
Villa, S. [1 ]
Nicolai, N. [1 ]
Biasoni, D. [1 ]
Salvioni, R. [1 ]
Valdagni, R. [1 ]
Bajetta, E. [1 ]
Procopio, G. [1 ]
机构：
[1] Fondazione IRCCS, Ist Nazl Tumori, Milan, Italy
来源：
ANTICANCER RESEARCH | 2010年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
278
引用
收藏
页码：1536 / 1536
页数：1
相关论文
共 50 条
  • [21] A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085)
    Yu, E.
    Massard, C.
    Gross, M.
    Wilding, G.
    Posadas, E.
    Culine, S.
    Carducci, M. A.
    Trudel, G.
    Paliwal, P.
    Sternberg, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC)
    Beer, T. M.
    Smith, D. C.
    Hussain, A.
    Alonso, M.
    Wang, J.
    Giurescu, M.
    Wang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer
    Taplin, Mary-Ellen
    Regan, Meredith M.
    Ko, Yoo-Joung
    Bubley, Glenn J.
    Duggan, Stephen E.
    Werner, Lillian
    Beer, Tomasz M.
    Ryan, Christopher W.
    Mathew, Paul
    Tu, Shi-Ming
    Denmeade, Samuel R.
    Oh, William K.
    Sartor, Oliver
    Mantzoros, Christos S.
    Rittmaster, Roger
    Kantoff, Philip W.
    Balk, Steven P.
    CLINICAL CANCER RESEARCH, 2009, 15 (22) : 7099 - 7105
  • [24] Comparison of Ketoconazole and Estramustine for Treating Patients with Castration-Resistant Prostate Cancer
    Yun, Bu Hyeon
    Hwang, Eu Chang
    Yoo, Dong Hoon
    Hwang, In Sang
    Kim, Sun-Ouck
    Jung, Seung Il
    Kang, Taek Won
    Kwon, Dong Deuk
    Park, Kwangsung
    Ryu, Soo Bang
    KOREAN JOURNAL OF UROLOGY, 2011, 52 (11) : 746 - 751
  • [25] A PHASE II STUDY OF SB939 IN PATIENTS (PTS) WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC)
    Eigl, B. J.
    North, S.
    Winquist, E.
    Powers, J.
    Good, J.
    Sharma, M.
    Squire, J.
    Cox, M.
    Eisenhauer, E. A.
    Chi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 304 - 304
  • [26] Docetaxel and curcuminoids combination in patients with castration-resistant prostate cancer: A phase II study
    Mahammedi, H.
    Pouget, M.
    Planchat, E.
    Cure, H.
    Durando, X.
    Van-Praagh, I.
    Savareux, L.
    Abrial, C.
    Chollet, P.
    Eymard, J. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S696
  • [27] Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
    Michaelson, M. D.
    Bellmunt, J.
    Hudes, G. R.
    Goel, S.
    Lee, R. J.
    Kantoff, P. W.
    Stein, C. A.
    Lardelli, P.
    Pardos, I.
    Kahatt, C.
    Nieto, A.
    Cullell-Young, M.
    Lewis, N. L.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1234 - 1240
  • [28] A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC)
    Bilusic, M.
    Gulley, J. L.
    Heery, C.
    Apolo, A. B.
    Arlen, P. M.
    Rauckhorst, M.
    McMahon, S.
    Dahut, W. L.
    Schlom, J.
    Madan, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [29] A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel
    Beardsley, E. K.
    Saad, F.
    Eigl, B.
    Venner, P.
    Hotte, S.
    Winquist, E.
    Ko, Y. J.
    Sridhar, S. S.
    Chi, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] MLL translocation in two castration-resistant prostate cancer (CRPC) patients.
    Chowdry, Rajasree Pia
    Ledet, Elisa M.
    Phelan, Mary C.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345